Objective: Concession and endothelial defect caused skin flap failure by thrombus. Our study aimed to support flap survive by an anticoagulant agent. Materials and Methods: On this study was used 14 Wistar Albino female rats who are separated control (n=7) and ticagrelor (n=7) groups. Dorsal skin flaps were elevated and sutured same incision area. Ticagrelor was infused 20 mg/kg before 24 hour and 10 mg/kg after operation, each 12 hour, 10 days. % 0.9 NaCl infused for control group. After 10 days, flaps were evaluated topographicly and histochemicaly. Results: Flap survival rate on control group % 62,84(43,40-69,83) and on ticagrelor group % 66,77(57,88-72,68) evaluated. Histopathologycal flap necrosis determined 1/3 distal and proximal parts were same but, central 1/3 part of flap on ticagrelor group has less necrosis than control group. That difference was supported statistical (p<0.05). Conclusion: Conclusion of study; Ticagrelor would increase flap viability and we could use ticagrelor as an alternative drug for flap survive.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
